Tonix Pharma (TNXP) AI Stock Analysis

• Market Cap: $111.08M
• Dividend Yield: N/A
• Average Volume (3M): 2.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 29.94%
• EPS Growth: -241.81%
• Country: US
• Employees: 81
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -29.46
• Shares Outstanding: 6,877,816
• 10 Day Avg. Volume: 1,118,562
• 30 Day Avg. Volume: 2,043,462
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 14.68
• Price to Cash Flow (P/CF): -2.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $70.00
• Price Target Upside: 311.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Tonix Pharma's stock score reflects significant recent corporate achievements that could enhance market entry and product development. However, profitability challenges and overbought technical indicators present cautionary factors.

Tonix Pharma Business Overview & Revenue Model

Company Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

How the Company Makes Money

Tonix Pharmaceuticals generates revenue primarily through the development and commercialization of its pharmaceutical products. As a clinical-stage company, its main revenue streams are expected to come from upfront payments, milestone payments, and royalties from partnerships or licensing agreements with larger pharmaceutical companies. These collaborations are crucial as they provide the financial resources and market access needed to advance the development and commercialization of its drug candidates. Additionally, Tonix may receive grant funding or government support for research and development efforts, particularly for projects in the public health domain, such as their COVID-19 vaccine and therapeutic programs. However, as of now, the company does not have any products approved for sale, and its revenue generation is contingent upon the successful development and commercialization of its pipeline candidates.

Tonix Pharma Financial Statement Overview

Summary

Tonix Pharma shows substantial revenue growth, yet struggles with profitability and cash flow. A strong equity base is a positive, but continued losses could pressure financial sustainability.

Income Statement

Tonix Pharma has shown substantial revenue growth from prior years, with total revenue increasing significantly from $0 to $10.09 million in 2024. However, profitability remains a challenge as indicated by negative EBIT and EBITDA margins. The net profit margin is nonexistent due to zero net income, suggesting the company is still in a heavy investment phase, typical for the biotechnology industry.

Balance Sheet

The company's balance sheet shows a healthy equity base with a debt-to-equity ratio of approximately 0.06, indicating low financial leverage. The equity ratio is strong at 85.7%, reflecting a robust capital structure. However, consistent net losses over the years suggest potential pressures on financial sustainability if cash reserves dwindle without profitability improvements.

Cash Flow

Cash flow analysis reveals a negative free cash flow, though the company has improved its operating cash flow situation compared to previous years. The significant financing cash flow indicates reliance on external funding to support operations. The cash flow to net income ratios are not meaningful due to the lack of net income.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.09M	7.77M	0.00	0.00	0.00
	Gross Profit
2.33M	3.03M	-112.09M	-92.31M	-50.51M
	EBIT
-136.70M	-118.38M	-112.09M	-92.31M	-50.51M
	EBITDA
-71.73M	-114.09M	-110.84M	-92.26M	-50.48M
	Net Income Common Stockholders
-130.04M	-116.66M	-116.88M	-92.29M	-52.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
98.78M	24.95M	120.23M	178.66M	77.07M
	Total Assets
162.89M	154.46M	225.69M	240.90M	98.18M
	Total Debt
8.12M	9.81M	760.00K	956.00K	1.31M
	Net Debt
-90.66M	-15.13M	-119.47M	-177.70M	-75.76M
	Total Liabilities
23.33M	48.93M	18.51M	22.18M	10.54M
	Stockholders Equity
139.56M	105.53M	207.18M	218.72M	87.65M
Cash Flow		Free Cash Flow
-61.05M	-109.90M	-146.20M	-110.86M	-57.13M
	Operating Cash Flow
-60.92M	-102.00M	-98.05M	-75.56M	-48.57M
	Investing Cash Flow
-120.00K	-29.07M	-48.15M	-35.31M	-8.56M
	Financing Cash Flow
134.87M	36.52M	87.84M	212.49M	123.11M

Tonix Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNXP, the sentiment is Negative. The current price of 17 is below the 20-day moving average (MA) of 20.11, above the 50-day MA of 15.11, and below the 200-day MA of 26.91, indicating a neutral trend. The MACD of -0.19 indicates Positive momentum. The RSI at 47.50 is Neutral, neither overbought nor oversold. The STOCH value of 30.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNXP.

Tonix Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	59 Neutral	$111.08M	―	-106.12%	―	29.94%	-241.81%
XCUR	57 Neutral	$73.16M	―	-197.92%	―	―	76.04%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
CYCN	45 Neutral	$7.72M	―	-30.36%	―	―	86.52%
ANVS	38 Underperform	$25.33M	―	-3159.09%	―	―	68.75%
EPIX	32 Underperform	$73.24M	―	-23.98%	―	―	-19.93%
KZIA	31 Underperform	$4.41M	―	-2639.52%	―	―	19.58%

Tonix Pharma Corporate Events

Tonix Pharma’s TNX-102 SL Advances in FDA Process

On March 24, 2025, Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for the New Drug Application of TNX-102 SL, a product candidate for fibromyalgia management. This development could streamline the approval process, potentially accelerating the product’s market entry and impacting the company’s operations and market positioning positively.

Tonix Pharma Secures Grant for TNX-801 Vaccine Development

On March 10, 2025, Tonix Pharmaceuticals announced receiving a $50,000 grant from the Medical CBRN Defense Consortium to support the development of its TNX-801 vaccine candidate for mpox and smallpox. The grant will aid in creating a commercialization plan for TNX-801, which has shown promising results, including being significantly less virulent than traditional smallpox vaccines and providing durable protection in animal models.

Tonix Pharma Appoints New Chief Technical Officer

On February 27, 2025, Tonix Pharma Limited, a subsidiary of Tonix Pharmaceuticals Holding Corp., signed an employment agreement with Siobhan Fogarty, the Chief Technical Officer. The agreement includes an annual salary, bonus eligibility, and equity compensation, with a 180-day notice period for termination, reflecting standard industry practices.

Tonix Pharma Highlights Fibromyalgia Treatment Success at Congress

On March 3, 2025, Tonix Pharmaceuticals presented data at the 7th International Congress on Controversies in Fibromyalgia, highlighting the effectiveness of their transmucosal sublingual cyclobenzaprine (TNX-102 SL) in reducing pain associated with fibromyalgia through improved non-restorative sleep. This presentation underscores Tonix’s commitment to addressing fibromyalgia and strengthens its position in the pharmaceutical industry by showcasing successful results from two Phase 3 studies.

Tonix Pharma Announces Promising Phase 1 Trial Results

On February 6, 2025, Tonix Pharmaceuticals announced encouraging Phase 1 trial results for its TNX-1500 product, a next-generation anti-CD40L monoclonal antibody, in healthy participants. The trial demonstrated that TNX-1500 was well-tolerated and effective in modulating immune responses, showing potential as a superior option in preventing organ transplant rejection with reduced toxicity compared to existing immunosuppressive treatments.

Tonix Pharma Promotes Fogarty to Chief Technology Officer

Tonix Pharmaceuticals Holding Corp. promoted Siobhan Fogarty to Chief Technology Officer on February 3, 2025. Ms. Fogarty, who has been with the company since 2016, is expected to leverage her extensive experience in product development to enhance the company’s technological capabilities and industry positioning.

Tonix Pharma Strategic Moves: Loan Termination and Stock Split

On February 3, 2025, Tonix Pharmaceuticals terminated a Loan Agreement by paying off $9.6 million, which included a prepayment fee. Additionally, Tonix’s Board approved a 1-for-100 reverse stock split to meet NASDAQ’s minimum bid price requirement for continued listing, effective February 5, 2025. This strategic move aims to stabilize Tonix’s market position, ensuring compliance with NASDAQ rules and potentially affecting the stockholders’ equity structure due to changes in share count.